





Conference Agenda-at-a-Glance

2020 Fall Conference

September 24-27, 2020



Virtual – Eastern Daylight Time

THURSDAY, September 24, 2020 - GI/Nutrition and General Pediatrics

9:45am-10:00am	<p>Welcome Shannon Manzi, PharmD, President of PPA</p>
10:00am-10:30am	<p>That Burning Pain, It's Not WOW, It's EOE (Eosinophilic Esophagitis) Jill Morgan, PharmD- University of Maryland School of Pharmacy, Baltimore, MD 0180-0000-20-301-L01-P (0.5 CE hours)</p> <ol style="list-style-type: none"> 1. Compare and contrast patient symptoms for GERD and EoE 2. Develop Treatment recommendations for pediatric patients with EoE 3. Review recent literature on the treatment of EOE since guidelines were published
10:30am-11:00am	<p>Pass the Salt: Sodium Supplementation in Intestinal Surgical Patients Shengda Ma, PharmD and Jessica Forster, PharmD- UC Davis Children's Hospital, Sacramento, CA 0180-0000-20-302-L01-P (0.5 CE hours)</p> <ol style="list-style-type: none"> 1. Understand the rationale for monitoring urine sodium in patients with short bowel syndrome, ostomies, or recent intestinal surgery 2. Develop dosing strategies and clinical monitoring targets when initiating sodium supplementation for these patient populations
11:00am-12:00pm	<p>A Practice Change is Coming: A Review of Asthma Guidelines Lisa Lubsch, PharmD- SIUe / Cardinal Glennon Children's Hospital, St. Louis, MO and Michelle Condren, PharmD- University of Oklahoma School of Medicine, Tulsa, OK 0180-0000-20-303-L01-P (1 CE hour, 1 BCPPS Recertification Unit)</p>  <ol style="list-style-type: none"> 1. Review key updates from the 2020 Global Initiative for Asthma Report and the coming National Asthma Education and Prevention Program Expert Panel 4 2. Discuss the preferred controller therapies for asthma treatment including the role of long-acting muscarinic antagonists and biologics 3. Compare low-dose inhaled corticosteroid / formoterol to short-acting beta2-agonist reliever therapy for acute asthma
12:00pm-1:30pm	<p><i>Lobby Lunch Sessions</i></p>
1:30pm-2:30pm	<p>Richard A. Helms Award of Excellence in Pediatric Pharmacy Practice: The Power of Networking and Lessons Learned from Omegaven Kathleen Gura, PharmD, BCNSP, FASHP, FPPAG Pharmacy Clinical Research Program Manager, Pharmacy Assistant Professor of Pediatrics, Harvard Medical School 0180-0000-20-304-L04-P (1 CE hour)</p> <ol style="list-style-type: none"> 1. Express how networking improves patient care and professional advancement 2. Explain why fish oil doesn't increase the risk of bleeding 3. Describe how fish oil monotherapy does not cause essential fatty acid deficiency 4. List the indications for Omegaven monotherapy
2:30pm-3:15pm	<p>The (Gluten-Free) Bread and Butter of Celiac Crisis Management Carlina Grindeland, PharmD- Sanford Children's Hospital, Fargo, ND and Julia Muzzy Williamson, PharmD- Sanford Children's Hospital / North Dakota State University, Fargo, ND 0180-0000-20-305-L01-P (0.75 CE hours)</p> <ol style="list-style-type: none"> 1. Describe the pathophysiology of celiac disease 2. Recognize the presentations of celiac disease and celiac crisis 3. Devise a treatment plan for celiac crisis 4. Discuss nutritional concerns in patients with poorly managed disease
3:15pm-3:30pm	<p>CYP2C19 and Proton Pump Inhibitor Dosing: An Introduction to the Newly Published Guidelines Samie Sabet, PharmD- University of Oklahoma-Tulsa School of Community Medicine, Tulsa, OK 0180-0000-20-306-L01-P (0.25 CE hours)</p> <ol style="list-style-type: none"> 1. Recognize the availability of the new CYP2C19 genotype based proton pump inhibitor dosing guideline published by the Clinical Pharmacogenomics Implementation Consortium 2. Identify proton pump inhibitors that are less affected by CYP2C19 metabolism as options when pharmacogenomic testing is not available 3. Utilize the new dosing recommendations when devising or modifying proton pump inhibitor regimens
3:30pm-4:30pm	<p>Optimizing Biological Therapies in Inflammatory Bowel Disease Titilola Afolabi, PharmD- Midwestern University College of Pharmacy, Glendale, AZ 0180-0000-20-307-L01-P (1 CE hour, 1 BCPPS Recertification Unit)</p>  <ol style="list-style-type: none"> 1. Discuss the role of biological therapies in pediatric patients with inflammatory bowel disease (IBD) 2. Identify patient specific factors that affect dosing and clinical outcomes in IBD 3. Describe the role of therapeutic drug monitoring (TDM) of biological therapies to optimize patient outcomes in pediatric patients with IBD 4. Design a treatment regimen by considering patient factors and applying TDM to optimize therapy with biologics in a pediatric patient with IBD
4:30pm – 6:30pm	<p>Happy Hour Exhibits</p>




Up to 5.0 CE Hours (2.0 BCPPS Recertification Units)

FRIDAY, September 25, 2020 - GI/Nutrition and General Pediatrics

10:00am – 10:30am	<p>Food Allergies and Anaphylaxis Sarah Smith, PharmD- St. John's University College of Pharmacy, New York, NY 0180-0000-20-308-L01-P (0.5 CE hours)</p> <ol style="list-style-type: none"> 1. Identify patients at risk for food allergy development and prevalence 2. Recognize the signs and symptoms of food related anaphylaxis 3. Effectively use treatment modalities for anaphylaxis and related symptoms 4. Recognize patients with risk for biphasic reaction and treat appropriately 5. Explore pharmacist's role in education of patients and caregivers about new therapeutic modalities for prevention of food allergies and reactions
10:30am-11:00am	<p>Finger Prickin' Good: Emerging Therapies for Type 1 Diabetes Kelly Matson, PharmD- University of Rhode Island, Kingston, RI 0180-0000-20-309-L01-P (0.5 CE hours)</p> <ol style="list-style-type: none"> 1. Describe the emerging literature for use of non-insulin treatment in type 1 diabetes and its role in pediatric practice 2. Discuss statin use for cardio-protection in children and adolescents with type 1 diabetes 3. Assess vitamin D supplementation as a protective factor in type 1 diabetes
11:00am-12:00pm	<p>Clinical Biochemistry 101 - Treatment of Common Errors of Metabolism James Dice, PharmD- Children's Hospital of The King's Daughters, Norfolk, VA and Aaron Harthan, PharmD- OSF HealthCare Children's Hospital of Illinois, Peoria, IL 0180-0000-20-310-L01-P (1 CE hour, 1 BCPPS Recertification Unit)</p>  <ol style="list-style-type: none"> 1. Understand the general pathophysiology of inborn errors of metabolism 2. Recognize the symptoms and diagnostic criteria of common inborn errors of metabolism 3. Critique a therapeutic regimen in a patient presenting with a urea cycle disorder 4. Create a medication regimen for a patient with phenylketonuria 5. Differentiate between various over the counter products to maximize safety and efficacy in the treatment of inborn errors of metabolism
12:00pm-1:30pm	<p><i>Lobby Lunch Sessions</i></p>
1:30pm-2:30pm	<p>Non-Medical Use of Opioids Among Youth: Prescription for the Pharmacists' Role in Opioid Safety and Treatment Education Kelly Matson, PharmD- University of Rhode Island, Kingston, RI 0180-0000-20-311-L08-P (1 CE hour, 1 BCPPS Recertification Unit)</p>  <ol style="list-style-type: none"> 1. Describe recent trends in opioid use, overdose deaths, and opioid use disorder diagnoses among the adolescent and young adult population in the United States 2. Discuss risk and protective factors that influence the likelihood an adolescent or young adult will misuse or develop an opioid use disorder 3. Assess an adolescent or young adult patient using appropriate screening tools for opioid misuse or opioid use disorder and determine whether brief intervention or referral for treatment is needed 4. Develop a treatment approach centered on medications for opioid use disorder (MOUD) in an adolescent or young adult with opioid use disorder
2:30pm-3:00pm	<p>Preserving and Advocating Pediatric and Neonatal Pharmaceutical Care in Disasters Stephen Small, PharmD, Denver Health Medical Center, Denver, CO 0180-0000-20-312-L04-P (0.5 CE hours)</p> <ol style="list-style-type: none"> 1. Discuss direct and indirect challenges and vulnerabilities to pediatric and neonatal pharmaceutical care in disasters 2. List tools that pharmacists can use to anticipate and mitigate potential unintended consequences from a disaster response 3. Describe avenues for advocating on behalf of pediatric and neonatal populations when planning and reacting to disasters 4. Apply the above knowledge and tools to advocate for pediatric and neonatal patients in a hospital disaster response scenario
3:00pm-3:30pm	<p>New Ways to Scratch the Itch: What's Erupting with Atopic Dermatitis Allison Chung, PharmD- Auburn University, Harrison School of Pharmacy and University of South Alabama, Children's and Women's Hospital, Mobile, AL and Kim Benner, PharmD- Samford University and Children's of Alabama, Homewood, AL 0180-0000-20-313-L01-P (0.5 CE hours)</p> <ol style="list-style-type: none"> 1. Utilize recent evidence to recommend nonpharmacologic pharmacotherapy for affected atopic dermatitis (AD) patients 2. Given a patient case, recommend recently FDA approved agents for AD, including patient criteria, dosing and administration 3. Provide appropriate counseling on risks versus benefits of various agents for patients with AD 4. Understand the patient perspective of atopic dermatitis: barriers and choice of therapies 5. Review potential new therapies on the horizon
3:30pm-4:30pm	<p>What's New? Minding Migraine Mitigation with the Updated 2019 Guidelines Joanna Wrobel, PharmD- AMITA Health St. Alexius Medical Center, Chicago, IL, Emi Onuki, PharmD- Atlanta, GA, and Jamie Caruthers, PharmD- AdventHealth for Children, Orlando, FL 0180-0000-20-314-L01-P (1 CE hour)</p> <ol style="list-style-type: none"> 1. Design an effective treatment regimen for an acute migraine in a pediatric patient 2. Design an effective treatment regimen for associated symptoms of migraines in a pediatric patient 3. Identify and evaluate the available pharmacological options for preventive treatment of migraines in a pediatric patient 4. Develop a patient counseling plan in an effort to optimize migraine treatment and prevention in a pediatric patient
4:30pm-6:30pm	<p>Poster Presentations</p>



Up to 5.0 CE Hours (2 BCPPS Recertification Units)

SATURDAY, September 26, 2020 - Scholarship and Preceptor Development

9:45am-10:00am	<p>Welcome Shannon Manzi, PharmD, President of PPA</p>	
10:00am – 10:30am	<p>What Do You Mean: I Am Mentoring a Preceptor? Noelle Leung, PharmD and Elizabeth Autry, PharmD- University of Kentucky, Lexington, KY 0180-0000-20-315-L04-P (0.5 CE hours)</p> <ol style="list-style-type: none"> 1. Discuss the rationale for and design of a preceptor development committee and mentorship program 2. Identify areas where mentorship would be beneficial within preceptor programs 3. Design ways to increase preceptor involvement within residency programs 	
10:30am – 11:00am	<p>Feeling Hot and Cold After Pediatric Emergencies: Hot and Cold Debriefing with Pharmacy Learners Deborah Bondi, PharmD and Sana Said, PharmD- University of Chicago Medicine, Comer Children's Hospital, Chicago, IL 0180-0000-20-316-L04-P (0.5 CE hours)</p> <ol style="list-style-type: none"> 1. Describe the benefits of debriefing reported in the literature on performance and mental well-being in emergency response situations 2. Identify similarities and differences between the hot debrief and cold debrief process 3. Explain the benefits of debriefing for pharmacy learners 4. Develop a process for implementing debriefing for pharmacy learners at your institution 	
11:00am – 12:00pm	<p>Guiding New Preceptors to Mentor and Precept Tara Higgins, PharmD- UF Health Shands Hospital, Gainesville, FL 0180-0000-20-317-L04-P (1 CE hour, 1 BCPPS Recertification Unit)</p> <ol style="list-style-type: none"> 1. Determine precepting versus mentoring 2. Facilitate new practitioners and new preceptors meeting ASHP preceptor standards 3. Assessing readiness of pharmacists to be a preceptor 	
12:00pm-1:30pm	<i>Lobby Lunch Sessions</i>	
1:30pm-2:30pm	<p>Sumner J. Yaffe Lifetime Achievement Award in Pediatric Pharmacology and Therapeutics: Ontogeny of Pediatric Pharmacogenetics: Celebrating the Past and Vision for the Future J. Steven Leeder, PharmD, PhD Marion Merrell Dow Endowed Chair in Pediatric Precision Therapeutics, Children's Mercy Hospital Deputy Director, Children's Mercy Research Institute Professor of Pediatrics, University of Missouri-Kansas City School of Medicine Research Professor of Pediatrics, University of Kansas School of Medicine 0180-0000-20-318-L04-P (1 CE hour)</p> <ol style="list-style-type: none"> 1. Appreciate the close ties between pediatric pharmacogenetics and pediatric clinical pharmacology as the latter matured as a discipline 2. Understand the role of genetic variation as a factor contributing to variability in drug disposition and response in pediatric patients in the context of progress made over the past 40 years 3. Discuss strategies to generate data for translation of pediatric pharmacogenetic data into precision therapeutic tools for children 	
2:30pm-3:30pm	<p>Pros and Cons of the Layered Learning Model Caroline Sierra, PharmD and Erika Wass, PharmD- Loma Linda University School of Pharmacy, Loma Linda, CA 0180-0000-20-319-L04-P (1 CE hour)</p> <ol style="list-style-type: none"> 1. Effectively implement the layered learning model in a practice setting 2. Develop tools to empower residents to be effective educators of student pharmacists 3. Discuss challenges within the layered learning model unique to the practice of pediatric pharmacy 	
3:30pm-4:00pm	<p>Precepting the Non-Peds PGY2 Lauren Buenger, PharmD- Riley Hospital for Children at IU Health, Indianapolis, IN 0180-0000-20-320-L04-P (0.5 CE hour, 0.5 BCPPS Recertification Units)</p> <ol style="list-style-type: none"> 1. Compare objectives and requirements between ASHP PGY2 programs of different specialties 2. Develop strategies to tailor a rotation to a non-pediatric PGY2 learner's needs 	
4:00pm-4:30pm	<p>All Hands On Deck: Improving Hands-On Learning Jenny Steinbrenner, PharmD- Nationwide Children's Hospital, Columbus, OH 0180-0000-20-321-L04-P (0.5 CE hour, 0.5 BCPPS Recertification Units)</p> <ol style="list-style-type: none"> 1. Discuss the benefits on hands-on learning 2. Identify methods to incorporate hands-on learning and simulations into your rotation 3. Design a practice model conducive for layered learning - Implement various methods of evaluation and feedback 	
4:30pm – 6:30pm	Residency Showcase	

Up to 5.0 CE Hours (2 BCPPS Recertification Units)

SUNDAY, September 27, 2020 - Scholarship and Preceptor Development

10:00am – 10:15am	<p>Flipped APPE: When You and Your Students Cannot Come to the Hospital Due to a Pandemic Mary Petrea Cober, PharmD- Akron Children's Hospital/Northeast Ohio Medical University, Akron, OH and Sarrah Hein, PharmD- Akron Children's Hospital, Akron, OH 0180-0000-20-322-L04-P (0.25 CE hours)</p> <ol style="list-style-type: none"> 1. Discuss the preparation and implementation of a virtual APPE experience
10:15am – 10:30am	<p>Don't Let Their Empathy Tank Hit E Amy Holmes, PharmD- Brenner Children's Hospital, Winston-Salem, NC 0180-0000-20-323-L04-P (0.25 CE hours)</p> <ol style="list-style-type: none"> 1. Discuss strategies for developing empathy in learners
10:30am-11:00am	<p>Polishing the Presenter: Providing Positive Experiences for Development of Presentation Skills for Residents Pete Johnson, PharmD and Jamie Miller, PharmD- University of Oklahoma College of Pharmacy, Oklahoma City, OK 0180-0000-20-324-L04-P (0.5 CE hours)</p> <ol style="list-style-type: none"> 1. Identify the required ASHP residency objectives for PGY1 Pharmacy and PGY2 Pediatric Pharmacy residents focused on delivery of educational presentations 2. Recognize the resources and framework needed to support residents in developing a successful presentation 3. Develop a plan to prepare residents to utilize active learning in presentations 4. Implement a system for self-assessment and formative and summative feedback of resident presentations
11:00am-12:00pm	<p>Burnout and You: The Preceptors Role in Recognizing and Mitigating Burnout Janesha Thomas, PharmD- Studer Family Children's Hospital, Pensacola, FL and Chenita Carter, MS- Florida Agricultural and Mechanical University College of Pharmacy, Crestview, FL 0180-0000-20-325-L04-P (1 CE hour, 1 BCPPS Recertification Unit)</p>  <ol style="list-style-type: none"> 1. Discuss the level and risk factors for professional burnout as it relates to pharmacy practice 2. Summarize evidence of burnout in pharmacists and pharmacy preceptors 3. Given a case study, identify burnout and review ways to improve well-being and resilience in pharmacy preceptors
12:00pm-1:30pm	<p><i>Lobby Lunch Sessions</i></p>
1:30pm-2:30pm	<p>Soft Skills Make Strong Residents: A Residency Program to Instill Resiliency and Professionalism Robyn Keen, PharmD, Mallory Cowart, PharmD and Chelsea Ferguson, PharmD- Arnold Palmer Medical Center, Orlando, FL 0180-0000-20-326-L04-P (1 CE hour, 1 BCPPS Recertification Unit)</p>  <ol style="list-style-type: none"> 1. Understand the need for continued soft skill building during pharmacy residency training 2. Develop strategies for promoting resilience and professionalism in pharmacy residents 3. Design a pharmacy resident resilience program and a professional development structure that optimize opportunity for ongoing resident professional success
2:30pm-3:30pm	<p>What is Your Emotional Intelligene Score? Importance of Emotional Intelligence in Today's Workplace Mary Petrea Cober, PharmD- Akron Children's Hospital/Northeast Ohio Medical University, Akron, OH 0180-0000-20-327- L04-P (1 CE hour)</p> <ol style="list-style-type: none"> 1. Discuss emotional intelligence and its impact on an institution's or program's overall goals and objectives 2. Evaluate methods to increase emotional intelligence among team members or trainees 3. Design strategies to incorporate emotional intelligence within the workplace or training environment
3:30pm-4:30pm	<p>If At First You Don't Succeed...Remediating Student and Resident Learners in the Clinical Setting Norman Fenn, PharmD- The University of Texas at Tyler, Tyler, TX and Caroline Sierra, PharmD- Loma Linda University School of Pharmacy, Loma Linda, CA 0180-0000-20-328-L04-P (1 CE hour)</p> <ol style="list-style-type: none"> 1. Recognize the differences between teaching and remediating pedagogies 2. Review areas of improvement in individual learners 3. Develop a remedial plan to address learner deficiencies
4:30pm	<p>Adjourn</p>

Up to 5.0 CE Hours (2 BCPPS Recertification Units)